



Clearbridge's SAM Laboratory Receives Accreditation from College of American Pathologists

SINGAPORE, 15 October 2019 – Integrated healthcare company, **Clearbridge Health Limited** (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (“明策集团”), is pleased to announce that its subsidiary, SAM Laboratory Pte Ltd (“SAM Laboratory”), which provides laboratory testing services in Singapore, has received accreditation from College of American Pathologists (“CAP”), based on the results of a recent on-site inspection as part of the CAP Accreditation Programs.

Sam Laboratory was first awarded the CAP Accreditation in 2015 and is required to undergo inspection every two years. As a Private Hospitals and Medical Clinics (“PHMC”) licensed laboratory, SAM Laboratory offers a comprehensive suite of clinical diagnostic tests augmented by collaborations with global partners.

Being one of the few laboratories in Asia with the CAP Accreditation, SAM Laboratory continues to actively pursue collaborations with an asset-light strategy, while tapping into the latest advancements in precision medicine.

The U.S. federal government recognises the CAP Laboratory Accreditation Program, that begun in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program.

During the CAP accreditation process, designed to ensure the highest standards of care for all laboratory patients, inspectors examine the laboratory’s records and quality control procedures for the preceding two years. CAP inspectors also assess laboratory staff qualifications, equipment, facilities, safety program and records, and overall management.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said, “As we enter the era of mainstream application of precision medicine, the importance of diagnostics’ role in medicine will continue to grow.

Clinical laboratories certifications, like CAP Accreditation, pave the way for our diagnostic solutions to complement our regional healthcare platform, enabling us to provide more healthcare solutions in Asia.”

– END –

Issued on behalf of Clearbridge Health Limited by 8PR Asia Pte Ltd.



Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

About Clearbridge Health Limited

(Bloomberg Code: CBH:SP / Reuters Code: CLEA.SI / SGX Code: 1H3)

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises healthcare systems, medical clinics/centres and strategic equity investments in medical technology companies.

Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients. It is executing the above strategies by way of primary healthcare and healthcare systems that reside in nexus of high demand.

For more information, please visit us at www.clearbridgehealth.com.

About the College of American Pathologists

As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists ("CAP") serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP Annual Report at cap.org.

This press release has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.